The aim of this study was to investigate chemopreventive effects of berberine on intestinal tumor development in APCmin/+ mice. Methods: Four-week old APCmin/+ mice were treated with 0.05% or 0.1% berberine in selleck products drinking water for twelve weeks. Parameters of intestinal tumor development, cell proliferation and apoptosis, and tumor promoting signaling pathways were determined. Results: The total number of the intestine tumor in the untreated group (30.63 ± 1.69) was decreased by 39.6% by 0.05% berberine treatment (18.50 ± 1.51), and 62.5% by 0.1% treatment (11.50 ± 2.05). All sizes of tumor (> 2 mm, 1–2 mm,

and <1 mm) were significantly reduced in both berberine treatment groups. In 0.1% berberine-treated group, tumors in proximal, middle, distal segments of small intestine were significantly reduced by 53.7%, 55.3%, and 76.5%, and the percentage of PCNA and Ki-67 positive cells were decreased by 32% and 55%, respectively. Expression of cyclin Dl was also decreased. Apoptotic cell number was increased by 2.14 fold in the tumors. Gene microarray indicated different gene expression profiles, and Wnt and EGFR pathways may be involved. Furthermore, berberine treatment suppressed β-catenin and epidermal growth factor receptor activation, and down-regulated the expression of cyclooxygenase-2 and prostaglandin E2 production. Conclusion: Berberine can inhibit intestinal tumor

PARP inhibitor development in APCmin/+ mice, which is associated Ceramide glucosyltransferase with its activity against tumor cell proliferation and induction of apoptosis, indicating its translational potential against intestinal tumor. Key Word(s): 1. berberine; 2. intestinal neoplasms; 3. signaling pathways; 4. APCmin/+ mice; Presenting Author: ZHIPING YUAN Additional Authors: LIANZHEN YU, FANGYUAN XU, CHAO SUN, CHENGLONG YIN, YE ZHU, XIA PAN, RUIHUA

SHI, SHUPING YANG Corresponding Author: LIANZHEN YU Affiliations: the First Affiliated Hospital with Nanjing Medical University Objective: This study was designed to investigate the relationship between the dose-time and anti-tumor effect of DNA methyltransferases (DNMTs) inhibitor decitabine in human gastric cancer cell line MKN45. Methods: Human gastric cancer cell line MKN45 was treated with a dose range (0–20 μmol/L) of decitabine for 48,72 and 96 hours, respectively. Flow cytometric analysis of Annexin V-FITC/PI staining and CCK8 assays were used to study apoptosis and proliferation in MKN45 cells. RT-PCR and Real-Time PCR were used to examine the expression of Homeobox D10(HoxD10) at the mRNA levels. Cleaved-caspase3 expression was determined by Western blot. Results: (1) Annexin V-FITC/PI staining showed that decitabine induced apoptosis of MKN45 in a time-dependent manner. The maximal amount of proapoptosis effect 17.37 ± 1.10% was detected at 96 h with 20 μmol/L decitabine.(2) Decitabine was an effective inhibitor of MKN45 proliferation and the effect was time-dependent.